HOT LINE sessions: reserved for the first presentations of primary endpoints of recently completed trials.
- Abstracts should contain data of a recently completed clinical trial which has not been presented or published anywhere previously.
- Although the data may be submitted to a journal for consideration, they should absolutely not be published before the date of the presentation at the ESC Congress 2009.
CLINICAL TRIAL UPDATE sessions: open for new data or analyses of trials recently presented at previous meetings.
- Abstracts should report additional, but unpresented, analysis of important clinical trials whose main endpoints have recently been made public.
These sessions provide notable exposure and recognition for studies likely to impact clinical practice. The trials are selected by the ESC Congress Programme Committee with this in mind.
Policy
Speakers cannot present in more than one Hot Line / Clinical Trial Update Session. A speaker will receive complimentary registration.
Satellite Symposiums occurring prior to the Hot Line or Clinical Trial Update Sessions cannot present the data contained in these sessions. A symposium can be organised after the Hot Line or Clinical Trial Update Session. Prior presentation to the trial investigators is acceptable.
Abstracts submitted on the same trial through the standard abstract submission procedure for the ESC Congress 2009 (deadline of 14 February 2009) will be withdrawn from the programme if the trial is presented in a Hot Line or Clinical Trial Update Session. In this case, please indicate the abstract number(s) on the application form for Hot Line/Clinical Trial Update presentation.
Press conferences: will be conducted by the ESC Press Office, where presenters, or their representatives, will discuss the results of their trials with members of the press and address any questions that might arise during the press conference. Participation in these ESC press conferences is an integral part of the Hot Line process.
|
Embargo
Clinical trial results are embargoed until the time of the press conference. Clinical trial sponsors must comply with embargo. The embargo means that results from the trial cannot be presented or announced in any forum except at closed investigator meetings prior to the ESC news conferences.
Trialists who ignore the above-mentioned rules run the risk of being withdrawn from the programme on site. Failure of investigators or sponsors to honour this embargo will also jeopardise future acceptance of clinical trials of the sponsors and presentations of the principal investigator at Scientific Sessions of the ESC for a period of 2 years.
|